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Abstract
The regenerative potential of cardiosphere-derived cells (CDCs) for ischaemic heart disease has been demonstrated in mice, rats, pigs and a recently
completed clinical trial. The regenerative potential of CDCs from dog hearts has yet to be tested. Here, we show that canine CDCs can be produced
from adult dog hearts. These cells display similar phenotypes in comparison to previously studied CDCs derived from rodents and human beings.
Canine CDCs can differentiate into cardiomyocytes, smooth muscle cells and endothelial cells in vitro. In addition, conditioned media from canine
CDCs promote angiogenesis but inhibit cardiomyocyte death. In a doxorubicin-induced mouse model of dilated cardiomyopathy (DCM), intravenous
infusion of canine CDCs improves cardiac function and decreases cardiac fibrosis. Histology revealed that injected canine CDCs engraft in the mouse
heart and increase capillary density. Out study demonstrates the regenerative potential of canine CDCs in a mouse model of DCM.
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Introduction
Numerous animal studies [1–12] and the first-in-human CADUCEUS trial
[13, 14] have demonstrated the regenerative potential of cardiosphere-
derived cells (CDCs) in ischaemic cardiomyopathy. Like human beings,
veterinary patients such as domestic dogs also suffer from heart dis-
eases. For instance, the overall prevalence of dilated cardiomyopathy
(DCM) in Doberman Pinschers is greater than 50% [15]. Once heart fail-
ure occurs, only palliative and sympathetic treatments exist. It is unknown
whether canine CDCs could be derived from adult dogs and whether they
are as potent as their human and rodent counterparts in cardiac regenera-
tion. On the other hand, there is a growing need to improve (large) animal
models for cell-based regenerative medicine [16]. Dogs with naturally
occurring heart diseases may serves as animal models of human dis-
eases. Here, we derived CDCs from the adult dog heart and tested their
regenerative potency in various in vitro and in vivo assays.
Materials and methods
Derivation and culture of Canine CDCs
Canine CDCs were generated and expanded as described [17] from myocar-
dial specimens of a healthy dog heart donor [10, 13]. This tissue was
surgically collected from the right ventricle of a 2-year old canine. An approxi-
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mately, 6 mm 9 6 mm piece of myocardial tissue was separated and
washed with PBS (Life Technologies, Carlsbad, CA, USA). The tissue sample
was then cut into smaller biopsy-sized pieces, and washed three times with
PBS, followed by enzymatic digestion at 37°C in 5 mg/ml collagenase IV solu-
tion (Sigma-Aldrich, St. Louis, MO, USA) for 5 min. Iscove’s Modified Dul-
becco’s Media (IMDM; Life Technologies, Carlsbad, CA, USA) containing 20%
foetal bovine serum (FBS; Corning) is then added to the sample to inactivate
the collagenase. After that, the tissue samples were further minced into smal-
ler tissue explants (~0.5 9 0.5 mm) before plating. Approximately, 50 pieces
of tissue explants were then placed onto a fibronectin-coated plate with
approximately 1.5 cm between each explant and covered with 2 ml of IMDM
with 20% FBS overnight to aid the attachment of tissue explants. The cultures
were maintained in IMDM with 20% FBS and media change was performed
every other day. In about 1 week, cells started to outgrow from the tissue ex-
plants. Once these outgrowth cells are about 70–80% confluent, they were
harvested by 5–10 min. of incubation with TryPLE SelectTM (Life Technolo-
gies). The cells were then seeded into an Ultra-Low-attachment flask (Corning)
at a density of 100,000 cells/cm2 and cultured in IMDM with 10% FBS. Phase-
bright canine cardiospheres (CSps) started to form in 3–7 days. Canine CSps
were then collected from the low-attachment flasks and re-plated onto fibro-
nectin-coated surface to produce adherent canine CDCs. Canine CDCs were
cultured in IMDM with 20% FBS media and passaged every 3–5 days. We
used Passage 2-3 CDCs for all in vitro and in vivo testing. Canine mesenchy-
mal stem cells (MSCs) were derived from the femur bone marrow of the dog
donor and used as the Control cells. Canine MSCs were maintained in the
same aforementioned CDC culture media [11, 12].
Clonal growth assay
Canine CDCs were seeded into a 96 well plate at a density of 1 cells
per 100 ll per well. Only wells containing one cell were used for the
experiment. Clonal growth of canine CDCs were tracked with a phase-
bright microscope during 1-week period of time.
Flow cytometry analysis
Canine CDCs were characterized by flow cytometry as described [7, 10].
Flow cytometry was performed on canine CDCs using a FACScalibur and
LSR II (BD Biosciences, San Jose, CA, USA) and analysed using FlowJo
software (TreeStar, Ashland, OR, USA). Cells were incubated with anti-
bodies against CD105 (ab156756; Abcam, Cambridge, England), CD90
(bd555595; BD Biosciences), CD45 (mca1042a488; AbD Serotec, Kidling-
ton, United Kingdom), CD117 (c-kit; ab5631; Abcam) for 60 min. Isotype-
identical antibodies served as negative controls.
Immunocytochemistry analysis
In addition to flow cytometry analysis, canine CDCs were seeded onto
fibronectin-coated chamber slides, after which the cells were fixed with
4% paraformaldehyde (PFA), blocked/permeabilized with Protein Block
Solution (DAKO, Carpinteria, CA, USA) containing 1% saponin (Sigma-
Aldrich), and then stained with anti-CD105 (ab156756; Abcam), anti-
CD90 (mca1036g; AbD Serotec), anti-c-kit (ab5631; Abcam) and
anti-CD45 (mca1042a488; AbD Serotec) antibodies. Fluorescein isothio-
cyanate (FITC)-secondary antibodies (Abcam) were used in conjunction
with the aforementioned primary antibodies.
In vitro differentiation assay
Both canine MSCs and CDCs were cultured in the following differentia-
tion media for 12 days: (i) cardiomyocyte differentiation media: IMDM
with 1% N2 (Cat no. 12440; Gibco, Carlsbad, CA, USA), and 100 ng/ml
Heregulin-b1 (Cat no. 100-03; Peprotech, Rocky Hill, NJ, USA);
(ii) smooth muscle differentiation media: IMDM with 10 ng/ml platelet-
derived growth factor-beta (Cat no. 100-14B; Peprotech) and (iii) endo-
thelial differentiation media: IMDM with 50 ng/mL VEGF (Cat no. 100-
20A; Peprotech) [18]. After the differentiation process, the cells were
fixed with 4% PFA, blocked/permeabilized with Protein Block Solution
(DAKO) containing 1% saponin (Sigma-Aldrich), and then stained with
mouse anti- a-sarcomeric actin (a-SA) (Sigma-Aldrich), mouse anti-
smooth muscle actin (Sigma-Aldrich) and rabbit anti-von Willebrand
factor (Abcam) antibodies. FITC or Texas-Red secondary antibodies
were obtained from Abcam as well. Cell nuclei were counter-stained
with 4’,6-diamidino-2-phenylindole (DAPI).
Paracrine assay
Canine CDCs or MSCs were plated into a six-well plate and incubated in
plain (serum-free) IMDM at a density of 1 million cell per 1 ml per well
for 3 days. After that, the conditioned media (CM) from CDCs was har-
vested. Neonatal rat cardiomyocytes (NRCMs) were derived as
described [19, 20] and plated onto fibronectin-coated 6 well plate
(Corning) with 1 9 106 cells with Medium 199 (Gibco). Neonatal rat
cardiomyocytes were incubated with CDC-CM, MSC-CM, or plain IMDM
as the Control. After 3 days, cells were fixed with 4% PFA and apoptotic
cells were detected by terminal deoxynucleotidyl transferase dUTP nick
end labelling (TUNEL) assay using the In Situ Cell Death Detection Kit
(Roche Diagnostics, Mannheim, Germany), according to the manufac-
turer’s instructions and DAPI for nuclei. Myocyte size quantification was
performed by anti-a-SA antibody staining followed by cell area mea-
surement using the NIH Image J software (Bethesda, MD, USA).
The pro-angiogenic effects of CDC-CM were studied by endothelial
cell tube formation assay. Human umbilical vein endothelial cells (HU-
VECs; from ATCC) were seeded onto growth factor-reduced MatrigelTM
(BD Biosciences) in 96-well plates at a density of 2 9 104 cells per
well. 100 ll of CDC-CM or MSC-CM were added into the wells. After
4 hrs, the wells were imaged with a Nikon (Chiyoda, Tokyo, Tokyo,
Japan) white light microscope. The average tube length was then mea-
sured with NIH Image J Software.
Animal procedures
All animal work is compliant with Institutional Animal Care and Usage Com-
mittee at North Carolina State University. We employed an acute doxorubi-
cin-induced DCM model as previously described [21]. Briefly, 6- to 8-week
old female severe combined immunodeficiency mice (Charles River Labora-
tories, Wilmington, MA, USA) were given 10 mg/kg body weight intraperi-
toneally injected (bw) Doxorubicin to create acute DCM on Day 0. On Day
1, the mice were then randomized into the following two treatment groups
(n = 9–11 mice per group): (i) Saline Control: Mice receiving 100 ll PBS
injected through the tail vein; (ii) Cell Treatment: Mice receiving 100 ll of
1 9 106 canine CDCs in 100 ll PBS injected through the tail vein. Blinded
echocardiography was performed by a single observer, at day 0 and 7 after
CDCs or PBS, for the measurement of cardiac function. Mice were
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anaesthetized with a 1.5% isofluorane-oxygen mixture and two-dimensional
long axis images were record from the left caudal (apical) view, using a Phi-
lips CX30 ultrasound system couple with a L15 high-frequency probe. Two-
dimensional guided M-mode images at chordae tendineae level were evalu-
ated. M-mode measurements of left ventricle end-diastolic and end-systolic
dimensions (LVEDD and LVESD, respectively) were performed by using the
leading-edge method of the American Society of Echocardiograph [22]. For
estimation of each parameter, the average of three measurements from
three different cycles in an image was obtained. Left ventricular end-dia-
stolic and systolic volumes (LVEDV and LVESV, respectively) were calcu-
lated by the biplane method of disks (modified Simpson’s rule). Ejection
fraction (EF) was determined by using (LVEDV – LVESV/LVEDV) 9 100%,
and fractional shortening (FS) was calculated from the M-mode echocardi-
ography images as (LVEDD – LVESD/LVEDD) 9 100%.
Histology
All animals were killed 8 days after treatment. Mouse hearts were har-
vested and frozen in Optimal Cutting Temperature (OCT) compound
(Tissue-Tek, Torrance, CA, USA). Cryo-sections (5 lm thick) were pre-
pared. Masson’s trichrome staining was performed as per manufacturer’s
instructions [HT15 Trichrome Staining (Masson) Kit; Sigma-Aldrich].
Fibrosis area was measured by NIH Image J as previously described [23].
For immunofluorescence staining, mouse heart cryosections were fixed
with 4% PFA, blocked/permeabilized with Protein Block Solution (DAKO)
containing 1% saponin (Sigma-Aldrich), and then stained with anti-a-SA
(Sigma-Aldrich) and anti-von Willebrand factor (Abcam) antibodies. FITC
or Texas-Red secondary antibodies were obtained from Abcam and used
in conjunction with these primary antibodies. Images were taken by a
Zeiss (Jena, Germany) confocal microscopy system.
Statistical analysis
Results are presented as mean  SD unless specified otherwise. Compar-
isons between any two groups were performed with two-tailed unpaired
Student’s t-test. Comparisons among more than two groups were per-
formed with one-way ANOVA followed by post hoc Bonferroni correction.
Differences were considered statistically significant when P < 0.05.
Results
Generation of canine CDCs
Using a three-stage ‘adhesion-suspension-adhesion’ culture process
(Fig. 1A), we derived CDCs from dog myocardial tissues. Both phase-
bright and stromal-like cells started to outgrow from the canine heart
tissue explants in a week after plating onto fibronectin-coated surfaces.
Those outgrowth cells become confluent in ~2–3 weeks (Fig. 1B).
When seeded on low-attachment surfaces (to discourage cell attach-
ment), the outgrowth cells spontaneously aggregate into three-dimen-
sional canine cardiospheres (Fig. 1C). To streamline the cardiosphere
forming process, we used Ultra-Low attachment surface instead of the
previously reported poly-D-lysine coating method. We demonstrated
that cardiosphere formation and the potency of the resulted CDCs of
the Ultra-Low method are indistinguishable from those of the poly-D-
lysine method (Fig. S1). When replated onto a fibronectin-coated sur-
face, the cardiospheres dissociated into single cells which we termed
CDCs (Fig. 1D and E). One biopsy-sized canine heart tissue can gener-
ate 50–200 millions of Passage 0 CDCs. When maintained and pas-
saged in IMDM with 20% FBS, canine CDCs can further undergo 25–
30 doublings in 35 days (Fig. 1F). Clonal growth was observed in
canine CDCs (Fig. 1G). Flow Cytometry analysis and immunocyto-
chemistry (Fig. 1H) revealed that canine CDCs were highly positive for
CD105 while being negative for haematopoietic marker CD45. Only a
negligible fraction of canine CDCs express CD90 and ckit. As a positive
control, canine MSCs uniformly express CD90 (Fig. S2).
Differentiation potential of canine CDCs
After 12 days into differentiation, around 20% of canine C DCs started
to express cardiomyocyte marker a-SA (Fig. 2A and B) or cardiac tro-
ponin I (Fig. S3) while only ~5% of canine MSCs expressed a-SA
(Fig. 2A and B). Instead, canine MSCs were potent in differentiation
into smooth muscle cells: ~90% of canine MSCs express alpha
smooth muscle actin. The endothelial differentiation potentials of
canine CDCs and MSCs were similar. These assays confirmed the car-
diovascular differentiation potential of canine CDCs.
Paracrine assays on canine CDCs
Incubation in CDC-CM increased the size/spreading of NRCMs (CDC-
CM versus IMDM: 1586.2  87.7 versus 1030.6  52.5 lm2)
(Fig. 3A), while MSC-CM did not have any positive effects on cardio-
myocyte size (997.1  56.7 lm2). In addition, CDC-CM promoted
the contractility of NRCMs as compared IMDM and MSC-CM (Vid-
eos S1–S3). In addition, CDC-CM protects cardiomyocytes from
apoptosis: NRCMs incubated with IMDM and MSC-CM had a cell
apoptosis rates (gauged by TUNEL staining) of 12.1  2.1% and
12.3  2.0%, respectively, while NRCMs incubated with CDC-CM
had a markedly lower apoptosis rate of 5.3  1.3% (Fig. 3B). These
compound data suggest canine CDCs are capable of promoting car-
diomyocyte contraction and survival through paracrine mechanisms
[24]. Moreover, CDC-CM promotes tube formation of human umbili-
cal vein endothelial cells on MatrigelTM (Fig. 3C): average tube length
in MSC-CM versus CDC-CM: 19.5  1.2 versus 33.3  2.6 lm, sug-
gesting its pro-angiogenic role in cardiac regeneration.
Canine CDC treatment improves cardiac function
and reduces fibrosis
The animal study design is outline in (Fig. 4A). Heart sections were
stained with Masson’s Trichrome staining kit and analysed for fibrosis.
Canine CDC injection significantly reduced fibrosis when compared to
Control-treated hearts (Fig. 4B, Fig. S3) (fibrosis area % of hearts in
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Fig. 1 Derivation and culture of Canine CDCs. (A) Schematic diagram showing the derivation of canine CDC. (B) Outgrowth cells from plated myo-
cardial tissues. (C) Cardiospheres forming in suspension culture. (D and E) Cardiosphere-derived cells (CDCs). (F) Cumulative growth analysis on
population doublings of canine CDCs. (G) Clonal growth assay showing the progenies of a single canine CDCs at Day 1, 5 and 10. (H) Expressions
of CD105, CD90, ckit, CD45 by flow cytometry and immunocytochemistry in canine. MSC data (Fig. S2); scale bars = 50 lm in all images.
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Control versus CDC therapy: 13.2  1.4 versus 4.0  0.8%). The
bona fide therapeutic effects from stem cell therapy would be the
improvement of heart pump functions. Echocardiography was per-
formed at baseline and 7 days after cell or saline injection. Treatment
effects (DEF% and DFS%) were calculated as the change in cardiac
functions from the baseline. Saline injection had a negative treatment
effects as EFs and FSs deteriorated over the 1 week time (Fig. 4C and
D, black bars). Cardiosphere-derived cell treatment (Fig. 4C and D, red
bars) protected cardiac functions from deteriorating because of the
doxorubicin. These data suggest that canine CDC therapy mitigates
fibrosis and pump function deterioration in DCM.
Canine CDCs engraft in the mouse heart,
promotion of angiogenesis and apoptosis
reduction
DiI-positive canine CDCs were detected in the mouse heart (Fig. 5A).
However, very few engrafted cells acquired mature cardiomyocyte or
endothelial phenotypes. Mounting lines of evidence suggest that stem
cell transplantation (including CDCs) exerts benefit through paracrine
mechanisms, i.e. transplanted cells secrete factors to promote endog-
enous repair [24]. Cardiosphere-derived cell therapy significantly
increased vascular density in the DCM heart: vWF-positive vascula-
tures % of total nuclei in Control-treated hearts versus CDC-treated
hearts: 11  1.6 versus 30.4  2.9% (Fig. 5B and C). Cardiosphere-
derived cell treatment reduced apoptosis in the post-MI hearts (TUN-
EL-positive cells in Control versus CDC therapy: 1.44  0.23 versus
0.53  0.09%) (Fig. 5D and E).
Discussion
Only a few families in the world are not affected by cardiovascular dis-
eases. As a result of the magnitude-high prevalence-high incidence of
cardiovascular disease in the world, stem cell therapy offers a prom-
ising option for therapeutic cardiac regeneration. The last decade wit-
nessed a burst of cell therapy trials for ischaemic cardiomyopathy.
For the last 6 years, our lab has been studying CDCs. Results from a
recent clinical trial indicate that infusion of autologous CDCs in mild-
to-moderate heart attack patients reduces scar and increases viable
tissue. A Phase II clinical trial is ongoing to test the regenerative
potential of allogeneic CDCs in patients with recent MI [25].
Veterinary patients such as domestic dogs suffer from heart dis-
eases as well. For instance, it has recently been found that the overall
prevalence of DCM in Doberman Pinschers is greater than 50% [18].
The expected survival time after diagnosis is strikingly less than
2 months. The autosomal dominant inheritance pattern in Doberman
Pinschers is similar to most forms of DCM in human’s heart [26, 27].
Once heart failure has occurred, treatment is only symptomatic and
A B
Fig. 2 Cardiovascular differentiation of canine CDCs in vitro. (A) Representative fluorescent micrographs showing the expressions of aSA, aSMA and
vWF in canine CDCs and MSCs r in three differentiation conditions: CM diff: cardiomyocyte differentiation; SM diff: smooth muscle differentiation;
EC diff: endothelial cell differentiation. (B) Percentages of total cells that are positive for specific differentiation markers. * indicates P < 0.05 when
compared to cMSC; scale bars = 50 lm.
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palliative. It is intriguing to wonder whether CDCs can be derived from
donor dog hearts and used for therapeutic regeneration in dog
patients with DCM. In addition, there is a growing interest from grant
agencies such as National Institute of Health to use domestic dogs
with naturally occurring heart diseases as model systems for cell-
based cardiac regenerative therapies.
In this study, we demonstrate that canine CDCs can be derived
from adult dog hearts and they are very phenotypically similar to
human and rodent CDCs (Fig. 1H). However, canine CDCs have low
expressions in CD90 and ckit. Recent report from us and others has
shown that ckit expression is irrelevant to the overall therapeutic
benefit of CDCs and CD90 expression indeed undermines the regener-
ative potential of CDCs [18, 28]. Therefore, the low expressions in
CD90 and ckit should not affect the therapeutic benefits of canine
CDCs. Canine CDCs are cardiac stem cells and can express markers
of cardiomyocytes, smooth muscle cells and endothelial cells in vitro
(Fig. 2). Consistent with our previous findings, the cardiac differentia-
tion potential of canine CDCs is greater than canine MSCs [8].
Mounting lines of evidence indicate that CDCs exert their thera-
peutic benefit through paracrine mechanisms. We collected CM from
canine CDCs and MSCs and study its effects on cardiomyocytes and
endothelial cells. Compared to MSC-CM, CDC-CM is more potent in
promoting myocyte contraction, inhibiting myocyte cell apoptosis and




Fig. 3 Paracrine assay. (A) Representative fluorescent micrographs showing neonatal rat cardiomyocytes (NRCM) grown in plain IMDM, condition
media from canine MSC and condition media from canine CDC. Myocyte area were measured by NIH Image J software (n = 23). * indicates
P < 0.05 when compared to MSC-CM or IMDM. (B) Representative fluorescent micrographs showing NRCMs grown in: plain media, condition
media from canine MSC, condition media from canine CDC. Apoptotic cells were detected by TUNEL staining and quantified (n = 18). * indicates
P < 0.05 when compared to cMSC CM or IMDM. (C) Measurement of average tube length in HUVEC cells cultured on Matrigel and incubated in
conditioned media form canine CDCs or MSCs (n = 13). * indicates P < 0.05 when compared to cMSC CM; scale bars = 50 lm.
1810 ª 2015 The Authors.




Fig. 4 Cardiac function and fibrosis. (A)
Schematic diagram showing the design of
animal studies. (B) Representative Mas-
son’s Trichrome staining images and
quantification of fibrotic area (n = 3)
Whole section view (Fig. S3A). (C and D)
Change in ejection fraction (EF) and frac-
tional shortening (FS) form baseline mea-
surements (n = 9–11 animals per group);
scale bars = 100 lm. *indicates P < 0.05







Fig. 5 Canine CDC engraftment, pro-angio-
genic effects, apoptosis measurement. (A)
Representative micrographs showing the
engraftment of DiI-positive CDCs in the
DCM mouse heart. (B) Representative
micrographs showing vWF-positive vascu-
latures. (C) Quantification of vWF-positive
vasculatures (n = 9–14 animals per
group). (D) Representative micrographs
showing apoptosis. (E) Quantitation of cell
apoptosis (n = 6). * indicates P < 0.05
when compared to Dox + Saline treat-
ment; scale bars = 50 lm.
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Additional staining using cardiac troponin I is also included in the
supplemental data (Fig. S4).
We induced acute DCM in immunodeficiency mouse with injec-
tion of 10 mg/kg doxorubicin. This model has been reported to
successfully induce DCM in less than 7 days [19]. Injection of
canine CDCs ameliorates ventricular dysfunction (Fig. 4C) and
reduces cardiac fibrosis (Fig. 4B). Such observed therapeutic bene-
fits are not accompanied by sizable cell engraftment: only a few of
DiI-positive canine CDCs (Fig. 5A) were detected in the mouse
heart and even fewer differentiated into mature cardiac cells. The
mechanisms underlying the therapeutic benefits of CDCs are not
fully elucidated. It has been reported that CDCs are highly pro-
angiogenic. Following this lead, we found that canine CDC treat-
ment enhanced angiogenesis in the DCM heart (Fig. 5B). Cardio-
sphere-derived cell treatment also reduced apoptosis when
compared to no treatment (Fig. 5D). The reduction in fibrosis may
be a result of matrix metaloproteneases secreted by CDCs [29]. It
has also been reported that CDC therapy stimulates cardiomyocyte
proliferation and recruitment of endogenous cardiac stem cells [9].
Taking together, these mechanisms could explain the therapeutic
benefits of CDCs in DCM.
In summary, we derived canine CDCs from adult dog hearts and
showed their regenerative potential in a mouse model of induced
DCM. Future studies will focus on testing canine CDCs in dogs with
naturally occurring heart diseases such as DCM.
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